Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jan;206(1):92.e1-6.
doi: 10.1016/j.ajog.2011.07.023. Epub 2011 Jul 22.

Transplacental Transfer of Oseltamivir and Its Metabolite Using the Human Perfused Placental Cotyledon Model

Affiliations

Transplacental Transfer of Oseltamivir and Its Metabolite Using the Human Perfused Placental Cotyledon Model

Paul Berveiller et al. Am J Obstet Gynecol. .

Abstract

Objective: Given the lack of data regarding the use of oseltamivir (Tamiflu) during pregnancy, we aimed to evaluate the placental transfer of oseltamivir phosphate and its active metabolite oseltamivir carboxylate, using the perfused placental cotyledon model.

Study design: Cotyledons were coperfused with oseltamivir phosphate and oseltamivir carboxylate using the maximal concentrations described with a 75 mg, twice-daily oral dose. Main transfer parameters such as fetal transfer rate (FTR) and clearance index (CI) were assessed.

Results: Five placentas were coperfused with oseltamivir phosphate and oseltamivir carboxylate. The median FTR of oseltamivir phosphate was 8.5% (range, 5.0-11.6%) and the median CI was 0.3 (range, 0.2-0.6). Regarding oseltamivir carboxylate transplacental transfer, the median FTR was 6.6% (range, 3.9-9.7%), whereas the median CI was 0.2 (range, 0.2-0.5).

Conclusion: A transplacental transfer of oseltamivir phosphate and its metabolite oseltamivir carboxylate was detected and might have clinical relevance. Clinicians should be encouraged to report oseltamivir treatment outcomes during pregnancy.

Similar articles

See all similar articles

Cited by 10 articles

See all "Cited by" articles

Publication types

LinkOut - more resources

Feedback